Anesthesiologie - Urgentiegeneeskunde
  • Home
  • Updates
    • Nieuws
    • Artikel van de week
    • Tip van de week
    • Congres tips & reviews
    • Cursus Tips & Reviews
  • D-examen
  • Online Lectures
    • Resuscitation
    • Trauma
    • Airway Management
    • Prehospital Emergency Medicine
    • Crew Resource Management
    • ResusNL
  • Educatie
    • Apps
    • Podcasts
    • Blogs & Sites
    • Boeken
    • Congressen
    • Cursussen
  • Over ons

Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. The PROPPR Randomized Clinical Trial

2/3/2015

 
JAMA. 2015;313(5):471-482. doi:10.1001/jama.2015.12.

Importance  Severely injured patients experiencing hemorrhagic shock often require massive transfusion. Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood cells), defined as damage control resuscitation, has been associated with improved outcomes; however, there have been no large multicenter clinical trials.

Objective  To determine the effectiveness and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio.

Design, Setting, and Participants  Pragmatic, phase 3, multisite, randomized clinical trial of 680 severely injured patients who arrived at 1 of 12 level I trauma centers in North America directly from the scene and were predicted to require massive transfusion between August 2012 and December 2013.

Interventions  Blood product ratios of 1:1:1 (338 patients) vs 1:1:2 (342 patients) during active resuscitation in addition to all local standard-of-care interventions (uncontrolled).

Main Outcomes and Measures  Primary outcomes were 24-hour and 30-day all-cause mortality. Prespecified ancillary outcomes included time to hemostasis, blood product volumes transfused, complications, incidence of surgical procedures, and functional status.

Results  No significant differences were detected in mortality at 24 hours (12.7% in 1:1:1 group vs 17.0% in 1:1:2 group; difference, −4.2% [95% CI, −9.6% to 1.1%]; P = .12) or at 30 days (22.4% vs 26.1%, respectively; difference, −3.7% [95% CI, −10.2% to 2.7%]; P = .26). Exsanguination, which was the predominant cause of death within the first 24 hours, was significantly decreased in the 1:1:1 group (9.2% vs 14.6% in 1:1:2 group; difference, −5.4% [95% CI, −10.4% to −0.5%]; P = .03). More patients in the 1:1:1 group achieved hemostasis than in the 1:1:2 group (86% vs 78%, respectively; P = .006). Despite the 1:1:1 group receiving more plasma (median of 7 U vs 5 U, P < .001) and platelets (12 U vs 6 U, P < .001) and similar amounts of red blood cells (9 U) over the first 24 hours, no differences between the 2 groups were found for the 23 prespecified complications, including acute respiratory distress syndrome, multiple organ failure, venous thromboembolism, sepsis, and transfusion-related complications.

Conclusions and Relevance  Among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days. However, more patients in the 1:1:1 group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Even though there was an increased use of plasma and platelets transfused in the 1:1:1 group, no other safety differences were identified between the 2 groups.

Trial Registration  clinicaltrials.gov Identifier: NCT01545232

Link naar het Artikel (open Acces)

Role of the massive transfusion protocol in the management of haemorrhagic shock

1/29/2015

 
British Journal of Anaesthesia (2014) 113 (suppl 2): ii3-ii8.

Abstract:

The concept of rapid delivery of multiple blood products to the bedside of a massively haemorrhaging patient seems to be a logical approach to the management of the massively bleeding patient. However, controversy exists in the use of fixed blood component ratios. Assessing the extent of the coagulopathy through point-of-care testing might provide patients with product administration as needed, and avoid excessive transfusion and its associated complications.
Link naar het artikel (open acces)

    Categories

    All
    Airway Management
    Analgesia
    Bleeding
    Bloedverlies
    Brandwonden
    Cardiac Arrest
    Checklist
    CICO
    Coagulopathy
    CPR
    Cricothyrodotomy
    CRM
    Disaster Medicine
    Drugs
    ECLS
    ECMO
    ECPR
    Emergency Anesthesia
    Guideline
    Human Factors
    Hypotension
    Intubation
    Ketamine
    Military Trauma
    MTP
    Multidisciplinary
    OHCA
    Outcome
    Pediatric Resuscitation
    PHEM
    POCUS
    Prehospital
    Procedural Sedation
    Propofol
    Rapid Sequence Induction
    RCT
    Resuscitation
    Sedation
    Shock
    TBI
    Therapeutic Hypothermia
    Tranexaminezuur
    Transfusie
    Trauma
    Trauma Anesthesia
    Traumatic Brain Injury
    Trial
    TXA
    Ultrasound
    Video Laryngoscopy

    Archives

    October 2021
    August 2020
    November 2019
    October 2019
    August 2019
    January 2019
    August 2018
    July 2018
    January 2018
    December 2017
    October 2017
    September 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    September 2014
    June 2014

    RSS Feed

Anesthesiologie - Urgentiegeneeskunde
www.urgentiegeneeskunde.com



de gratis online resource over trauma-anesthesie, reanimatie, resuscitatie, airway management, prehospitale zorg en alles wat te maken heeft met de zorg voor de vitaal bedreigde patient.